CoChat

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines

Paíno, Teresa, Sarasquete, María E., Paiva, Bruno, Krzeminski, Patryk, San-Segundo, Laura, Corchete, Luis A., Redondo, Alba, Garayoa, Mercedes, García-Sanz, Ramón, Gutiérrez, Norma C., Ocio, Enrique M., San-Miguel, Jesús F. · 2014 · PLoS ONE
Cited by 22

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0092378

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 48

  1. JF San-Miguel, 2011, Can multiple myeloma become a curable disease, Haematologica, 96, 1246, 10.3324/haematol.2011.051169 · DOI
  2. A Hamburger, 1977, Primary bioassay of human myeloma stem cells, J Clin Invest, 60, 846, 10.1172/JCI108839 · doi:10.1172/jci108839
  3. M Chilosi, 1999, CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies, Mod Pathol, 12, 1101
  4. A Wei, 2003, Bone marrow immunohistology of plasma cell neoplasms, J Clin Pathol, 56, 406, 10.1136/jcp.56.6.406 · DOI
  5. J Wijdenes, 1996, A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1, Br J Haematol, 94, 318, 10.1046/j.1365-2141.1996.d01-1811.x · DOI · Paper page
  6. G Jego, 1999, Reactive plasmacytoses are expansions of plasmablasts retaining the capacity to differentiate into plasma cells, Blood, 94, 701, 10.1182/blood.V94.2.701 · DOI · Paper page
  7. G Jego, 2001, Interleukin-6 is a growth factor for nonmalignant human plasmablasts, Blood, 97, 1817, 10.1182/blood.V97.6.1817 · DOI · Paper page
  8. KL Calame, 2001, Plasma cells: finding new light at the end of B cell development, Nat Immunol, 2, 1103, 10.1038/ni1201-1103 · DOI · Paper page
  9. W Matsui, 2004, Characterization of clonogenic multiple myeloma cells, Blood, 103, 2332, 10.1182/blood-2003-09-3064 · DOI · Paper page
  10. W Matsui, 2008, Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance, Cancer Res, 68, 190, 10.1158/0008-5472.CAN-07-3096 · DOI · Paper page
  11. K Boucher, 2012, Stemness of B-cell progenitors in multiple myeloma bone marrow, Clin Cancer Res, 18, 6155, 10.1158/1078-0432.CCR-12-0531 · DOI
  12. K Yata, 2004, The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells, Leukemia, 18, 1891, 10.1038/sj.leu.2403513 · DOI
  13. D Chiron, 2012, The peripheral CD138+ population but not the CD138- population contains myeloma clonogenic cells in plasma cell leukaemia patients, Br J Haematol, 156, 679, 10.1111/j.1365-2141.2011.08904.x · DOI
  14. D Kim, 2012, CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells, Leukemia, 26, 2530, 10.1038/leu.2012.140 · DOI
  15. A Kukreja, 2006, Enhancement of clonogenicity of human multiple myeloma by dendritic cells, J Exp Med, 203, 1859, 10.1084/jem.20052136 · DOI · Paper page
  16. GM Fuhler, 2010, Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells, Exp Cell Res, 316, 1816, 10.1016/j.yexcr.2010.03.013 · DOI
  17. JH Christensen, 2012, Characterization of potential CD138 negative myeloma “stem cells”, Haematologica, 97, e18, 10.3324/haematol.2011.043125 · doi:10.3324/haematol.2011.043125
  18. S Greenstein, 2003, Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells, Exp Hematol, 31, 271, 10.1016/S0301-472X(03)00023-7 · DOI
  19. F Sanz-Rodriguez, 1999, Characterization of VLA-4-dependent myeloma cell adhesion to fibronectin and VCAM-1, Br J Haematol, 107, 825, 10.1046/j.1365-2141.1999.01762.x · DOI · Paper page
  20. Q Chen, 2005, The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells, Blood, 106, 698, 10.1182/blood-2004-11-4286 · DOI · Paper page
  21. MH Ma, 2003, The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents, Clin Cancer Res, 9, 1136
  22. B Paiva, 2011, Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma, Leukemia, 25, 697, 10.1038/leu.2010.320 · DOI
  23. X Carvajal-Vergara, 2005, Multifunctional role of Erk5 in multiple myeloma, Blood, 105, 4492, 10.1182/blood-2004-08-2985 · DOI
  24. NC Gutierrez, 2005, Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia, Leukemia, 19, 402, 10.1038/sj.leu.2403625 · DOI · Paper page
  25. JJ van Dongen, 2003, Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936, Leukemia, 17, 2257, 10.1038/sj.leu.2403202 · DOI · Paper page
  26. EM Ocio, 2009, Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks, Blood, 113, 3781, 10.1182/blood-2008-09-177774 · DOI
  27. S Zhou, 2001, The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype, Nat Med, 7, 1028, 10.1038/nm0901-1028 · DOI · Paper page
  28. L Li, 2011, Stem cell quiescence, Clin Cancer Res, 17, 4936, 10.1158/1078-0432.CCR-10-1499 · DOI · Paper page
  29. E Charafe-Jauffret, 2009, Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer Res, 69, 1302, 10.1158/0008-5472.CAN-08-2741 · DOI · Paper page
  30. D Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med, 3, 730, 10.1038/nm0797-730 · DOI · Paper page
  31. N Hosen, 2012, CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients, Leukemia, 26, 2135, 10.1038/leu.2012.80 · DOI
  32. H Li, 2008, PC3 human prostate carcinoma cell holoclones contain self-renewing tumor-initiating cells, Cancer Res, 68, 1820, 10.1158/0008-5472.CAN-07-5878 · DOI · Paper page
  33. A Roesch, 2010, A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth, Cell, 141, 583, 10.1016/j.cell.2010.04.020 · DOI · Paper page
  34. R Spisek, 2007, Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy, J Exp Med, 204, 831, 10.1084/jem.20062387 · DOI · Paper page
  35. J Jakubikova, 2011, Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications, Blood, 117, 4409, 10.1182/blood-2010-02-267344 · DOI
  36. S Yaccoby, 2005, The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype, Clin Cancer Res, 11, 7599, 10.1158/1078-0432.CCR-05-0523 · DOI
  37. J Jacak, 2013, Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout, J Biotechnol, 164, 525, 10.1016/j.jbiotec.2013.01.027 · doi:10.1016/j.jbiotec.2013.01.027
  38. A Chaidos, 2013, Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma, Blood, 121, 318, 10.1182/blood-2012-06-436220 · DOI · Paper page
  39. T Reya, 2001, Stem cells, cancer, and cancer stem cells, Nature, 414, 105, 10.1038/35102167 · DOI · Paper page
  40. LV Nguyen, 2012, Cancer stem cells: an evolving concept, Nat Rev Cancer, 12, 133, 10.1038/nrc3184 · DOI · Paper page
  41. S Reid, 2010, Characterisation and relevance of CD138-negative plasma cells in plasma cell myeloma, Int J Lab Hematol, 32, e190, 10.1111/j.1751-553X.2010.01222.x · DOI
  42. GG Wulf, 2001, A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia, Blood, 98, 1166, 10.1182/blood.V98.4.1166 · DOI · Paper page
  43. Y Luo, 2012, ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets, Stem Cells, 30, 2100, 10.1002/stem.1193 · DOI · Paper page
  44. JE Dick, 1996, Human stem cell assays in immune-deficient mice, Curr Opin Hematol, 3, 405, 10.1097/00062752-199603060-00002 · DOI
  45. LM Pilarski, 2000, Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID mice, Blood, 95, 1056, 10.1182/blood.V95.3.1056.003k26_1056_1065 · DOI
  46. E Van Valckenborgh, 2012, Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model, Leukemia, 26, 1436, 10.1038/leu.2011.373 · DOI
  47. T Paino, 2012, CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype, Haematologica, 97, 1110, 10.3324/haematol.2011.057372 · doi:10.3324/haematol.2011.057372
  48. T Paino, 2013, Reply to “Response to”CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype”. Haematologica 2012;97(7):1110–1114, Haematologica, 98, e10, 10.3324/haematol.2012.077727 · doi:10.3324/haematol.2012.077727

Cited by

See all 22

Metadata

Authors
Paíno, T., Sarasquete, M. E., Paiva, B., Krzeminski, P., San-Segundo, L., Corchete, L. A., Redondo, A., Garayoa, M., García-Sanz, R., Gutiérrez, N. C., Ocio, E. M., & San-Miguel, J. F.
Venue
PLoS ONE
Published
2014-03-21
Volume
9
Issue
3
Pages
e92378
ISSN
1932-6203
Cited by
22
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. https://app.cochat.ai/papers/10.1371/journal.pone.0092378
The paper
Paíno, T., Sarasquete, M. E., Paiva, B., Krzeminski, P., San-Segundo, L., Corchete, L. A., Redondo, A., Garayoa, M., García-Sanz, R., Gutiérrez, N. C., Ocio, E. M., & San-Miguel, J. F. (2014). Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138++ and CD138low Subpopulations in Multiple Myeloma Cell Lines. PLoS ONE. https://doi.org/10.1371/journal.pone.0092378

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.